VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
E La RoccaM C De Santis

Abstract

To report acute toxicities in breast cancer (BC) patients (pts) recruited in a prospective trial and treated with accelerated partial-breast irradiation (APBI) using Volumetric Modulated Arc Therapy (VMAT) delivered with a hypofractionated schedule. From March 2014 to June 2019, pts with early-stage BC (Stage I), who underwent breast conservative surgery (BCS), were recruited in a prospective study started at the National Cancer Institute of Milan. Pts received APBI with a hypofractionated schedule of 30 Gy in five daily fractions. Radiotherapy treatment (RT) was delivered using VMAT. Acute toxicity was assessed according to RTOG/EORTC criteria at the end of RT. Between March 2014 and June 2019, 151 pts were enrolled in this study. 79 Pts had right-side and 72 had left-side breast cancer. Median age was 69 (range 43-92). All pts presented with pathological stage IA BC, molecular classification was Luminal A in 128/151 (85%) and Luminal B in 23/151 (15%) cases. Acute toxicity, assessed at the end of RT, consisted of G1 erythema in 37/151 (24. 5%) pts and skin toxicities higher than G1, did not occur. Fibrosis G1 and G2 were reported in 41/151 (27. 1%) pts and in 2/151 pts (1. 3%), respectively. Edema G1 occurred in 8/151 (5. 3%)...Continue Reading

References

Feb 1, 1979·International Journal of Radiation Oncology, Biology, Physics·J R HarrisS Hellman
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J D CoxT F Pajak
Jun 29, 2001·International Journal of Radiation Oncology, Biology, Physics·K L BaglanF A Vicini
Jan 16, 2003·International Journal of Radiation Oncology, Biology, Physics·Kathy L BaglanFrank A Vicini
Sep 24, 2004·International Journal of Radiation Oncology, Biology, Physics·Silvia C FormentiJ Keith Dewyngaert
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas W Arthur, Frank A Vicini
May 27, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Mariella Mannino, John R Yarnold
Sep 12, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Birgitte V OffersenJens Overgaard
Nov 26, 2008·Acta Oncologica·Saleh BensalehMartin Borg
Apr 28, 2009·International Journal of Radiation Oncology, Biology, Physics·Jaroslaw T HepelDavid E Wazer
Jun 24, 2009·International Journal of Radiation Oncology, Biology, Physics·Benjamin D SmithJay R Harris
Aug 25, 2009·International Journal of Radiation Oncology, Biology, Physics·Lorenzo LiviGiampaolo Biti
Feb 26, 2010·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Csaba PolgárMiklós Kásler
May 7, 2010·International Journal of Radiation Oncology, Biology, Physics·Jian-Jian QiuFang-Fang Yin
Aug 17, 2010·Breast Cancer Research and Treatment·Umberto VeronesiPatrick Maisonneuve
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Mar 7, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Icro MeattiniLorenzo Livi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.